Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium difficile | 11 | 2016 | 23 | 3.360 |
Why?
|
| Clostridium Infections | 7 | 2019 | 11 | 2.620 |
Why?
|
| Enterocolitis, Pseudomembranous | 6 | 2015 | 14 | 2.070 |
Why?
|
| Cross Infection | 7 | 2019 | 28 | 1.710 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 241 | 0.890 |
Why?
|
| Health Personnel | 5 | 2022 | 126 | 0.860 |
Why?
|
| Humans | 40 | 2023 | 18430 | 0.770 |
Why?
|
| Adult | 24 | 2023 | 7910 | 0.750 |
Why?
|
| Accelerometry | 1 | 2021 | 37 | 0.750 |
Why?
|
| Young Adult | 13 | 2021 | 2518 | 0.690 |
Why?
|
| Pericarditis | 2 | 2018 | 14 | 0.660 |
Why?
|
| Myocarditis | 2 | 2018 | 18 | 0.620 |
Why?
|
| Vaccination | 5 | 2022 | 674 | 0.620 |
Why?
|
| Health Services | 2 | 2016 | 117 | 0.610 |
Why?
|
| Incidence | 9 | 2022 | 1314 | 0.610 |
Why?
|
| Viral Vaccines | 1 | 2018 | 15 | 0.610 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 17 | 0.610 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 168 | 0.610 |
Why?
|
| Vaccines, Attenuated | 1 | 2018 | 47 | 0.610 |
Why?
|
| Health Services for the Aged | 1 | 2018 | 15 | 0.610 |
Why?
|
| Population Surveillance | 3 | 2014 | 271 | 0.610 |
Why?
|
| Deprescriptions | 1 | 2018 | 8 | 0.600 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 39 | 0.590 |
Why?
|
| Male | 24 | 2022 | 10440 | 0.570 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 214 | 0.570 |
Why?
|
| Female | 25 | 2022 | 13136 | 0.550 |
Why?
|
| Exercise | 1 | 2021 | 495 | 0.540 |
Why?
|
| Public Health Surveillance | 2 | 2022 | 45 | 0.540 |
Why?
|
| Risk Management | 1 | 2016 | 5 | 0.540 |
Why?
|
| Middle Aged | 19 | 2022 | 8284 | 0.530 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.530 |
Why?
|
| Ambulatory Care | 2 | 2015 | 266 | 0.530 |
Why?
|
| Patient-Centered Care | 2 | 2017 | 228 | 0.520 |
Why?
|
| Aged | 15 | 2022 | 6417 | 0.500 |
Why?
|
| Medication Adherence | 2 | 2017 | 267 | 0.500 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 320 | 0.490 |
Why?
|
| Risk | 2 | 2022 | 552 | 0.480 |
Why?
|
| Decision Making | 2 | 2017 | 204 | 0.460 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2550 | 0.430 |
Why?
|
| Community-Acquired Infections | 2 | 2019 | 24 | 0.430 |
Why?
|
| Adolescent | 14 | 2021 | 3798 | 0.420 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 226 | 0.400 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 77 | 0.400 |
Why?
|
| Health Expenditures | 1 | 2012 | 82 | 0.390 |
Why?
|
| Viral Load | 2 | 2022 | 135 | 0.390 |
Why?
|
| Northwestern United States | 4 | 2021 | 58 | 0.380 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 444 | 0.370 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 2003 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 4 | 2016 | 142 | 0.330 |
Why?
|
| Colorado | 3 | 2014 | 211 | 0.310 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2010 | 142 | 0.310 |
Why?
|
| Personnel, Hospital | 1 | 2008 | 9 | 0.310 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 15 | 0.310 |
Why?
|
| Hospitals, Rural | 1 | 2007 | 6 | 0.300 |
Why?
|
| Hospitalization | 5 | 2022 | 847 | 0.280 |
Why?
|
| Qualitative Research | 2 | 2018 | 272 | 0.280 |
Why?
|
| Emergency Responders | 2 | 2021 | 4 | 0.240 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 290 | 0.240 |
Why?
|
| Risk Factors | 5 | 2023 | 3449 | 0.240 |
Why?
|
| Pharmacists | 2 | 2021 | 48 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2022 | 282 | 0.220 |
Why?
|
| Case-Control Studies | 5 | 2019 | 1173 | 0.220 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 743 | 0.220 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 21 | 0.210 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 44 | 0.200 |
Why?
|
| Vancomycin | 2 | 2012 | 3 | 0.200 |
Why?
|
| Prospective Studies | 7 | 2023 | 1314 | 0.200 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2014 | 254 | 0.200 |
Why?
|
| Angioedema | 1 | 2021 | 7 | 0.200 |
Why?
|
| Occupations | 1 | 2021 | 16 | 0.190 |
Why?
|
| Pharmacy | 1 | 2021 | 12 | 0.190 |
Why?
|
| Vital Signs | 1 | 2021 | 14 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 1389 | 0.190 |
Why?
|
| Occupational Diseases | 1 | 2021 | 42 | 0.190 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 249 | 0.180 |
Why?
|
| Physicians | 1 | 2021 | 141 | 0.180 |
Why?
|
| Time Factors | 4 | 2022 | 1136 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2012 | 701 | 0.170 |
Why?
|
| Patient Participation | 1 | 2021 | 144 | 0.170 |
Why?
|
| Veterans Health | 1 | 2019 | 21 | 0.170 |
Why?
|
| Logistic Models | 3 | 2015 | 962 | 0.170 |
Why?
|
| United States | 7 | 2023 | 4164 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2019 | 468 | 0.170 |
Why?
|
| Communication | 1 | 2021 | 202 | 0.170 |
Why?
|
| Railroads | 1 | 2019 | 5 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2015 | 2672 | 0.160 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 126 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 399 | 0.160 |
Why?
|
| Syncope | 1 | 2018 | 12 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 9 | 0.160 |
Why?
|
| Acute Pain | 1 | 2018 | 11 | 0.160 |
Why?
|
| Environment Design | 1 | 2019 | 68 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 17 | 0.150 |
Why?
|
| Length of Stay | 2 | 2010 | 183 | 0.150 |
Why?
|
| Health Surveys | 1 | 2019 | 269 | 0.150 |
Why?
|
| Life Change Events | 1 | 2018 | 31 | 0.150 |
Why?
|
| Infection Control | 2 | 2007 | 10 | 0.150 |
Why?
|
| Adolescent Health Services | 1 | 2018 | 43 | 0.150 |
Why?
|
| Infant | 3 | 2023 | 1245 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2016 | 2 | 0.140 |
Why?
|
| Child Health Services | 1 | 2018 | 129 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 232 | 0.140 |
Why?
|
| Recurrence | 1 | 2016 | 187 | 0.130 |
Why?
|
| Electronic Health Records | 3 | 2019 | 747 | 0.130 |
Why?
|
| Heart Failure | 1 | 2021 | 398 | 0.130 |
Why?
|
| Trimethoprim | 1 | 2015 | 4 | 0.130 |
Why?
|
| Child | 5 | 2023 | 2571 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2015 | 14 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2022 | 1143 | 0.130 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 15 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2018 | 161 | 0.130 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 39 | 0.130 |
Why?
|
| Patient Admission | 1 | 2016 | 76 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 80 | 0.130 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 4 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 197 | 0.130 |
Why?
|
| Vaccines | 1 | 2018 | 222 | 0.130 |
Why?
|
| Algorithms | 1 | 2016 | 241 | 0.120 |
Why?
|
| Self Administration | 1 | 2014 | 12 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2016 | 185 | 0.120 |
Why?
|
| Electronic Mail | 1 | 2014 | 53 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2023 | 1478 | 0.120 |
Why?
|
| Inpatients | 1 | 2014 | 80 | 0.120 |
Why?
|
| Quality of Life | 1 | 2018 | 529 | 0.120 |
Why?
|
| Outpatients | 1 | 2014 | 111 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2015 | 159 | 0.110 |
Why?
|
| Telephone | 1 | 2014 | 179 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 327 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 624 | 0.110 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.100 |
Why?
|
| Comorbidity | 1 | 2014 | 619 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 253 | 0.100 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 43 | 0.100 |
Why?
|
| Iowa | 2 | 2007 | 38 | 0.090 |
Why?
|
| Delivery, Obstetric | 1 | 2010 | 16 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 157 | 0.090 |
Why?
|
| California | 1 | 2016 | 2365 | 0.090 |
Why?
|
| Pregnancy | 2 | 2015 | 1516 | 0.080 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2008 | 2 | 0.080 |
Why?
|
| Administrative Personnel | 1 | 2008 | 6 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2008 | 20 | 0.080 |
Why?
|
| Infection Control Practitioners | 1 | 2007 | 1 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 39 | 0.080 |
Why?
|
| Immunization Programs | 1 | 2008 | 68 | 0.070 |
Why?
|
| Borrelia burgdorferi Group | 2 | 1998 | 2 | 0.070 |
Why?
|
| Lyme Disease | 2 | 1998 | 4 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 1998 | 9 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2018 | 120 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 392 | 0.060 |
Why?
|
| Arthritis, Infectious | 1 | 1982 | 1 | 0.050 |
Why?
|
| Yersinia Infections | 1 | 1982 | 1 | 0.050 |
Why?
|
| Arthritis, Reactive | 1 | 1982 | 1 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 3 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2022 | 4 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 7 | 0.050 |
Why?
|
| Thrombosis | 1 | 2022 | 11 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 64 | 0.050 |
Why?
|
| Primary Health Care | 2 | 2021 | 848 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2022 | 34 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 6 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 65 | 0.050 |
Why?
|
| Carrier State | 1 | 2021 | 8 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 7 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 243 | 0.050 |
Why?
|
| Sacrococcygeal Region | 1 | 2001 | 1 | 0.050 |
Why?
|
| Diskectomy | 1 | 2001 | 2 | 0.050 |
Why?
|
| Prednisolone | 1 | 2001 | 3 | 0.050 |
Why?
|
| Sciatica | 1 | 2001 | 2 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2001 | 3 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2001 | 16 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 90 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2021 | 1296 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 407 | 0.040 |
Why?
|
| Patient Comfort | 1 | 2018 | 3 | 0.040 |
Why?
|
| Fibromyalgia | 1 | 1998 | 4 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2018 | 4 | 0.040 |
Why?
|
| Oregon | 1 | 2019 | 222 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 32 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 36 | 0.040 |
Why?
|
| Nails, Malformed | 1 | 1997 | 2 | 0.040 |
Why?
|
| Pain Management | 1 | 2018 | 59 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1997 | 40 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 237 | 0.040 |
Why?
|
| Child Abuse | 1 | 2018 | 43 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2018 | 319 | 0.040 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 32 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 256 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 1996 | 1 | 0.030 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2017 | 110 | 0.030 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 22 | 0.030 |
Why?
|
| Parents | 1 | 2018 | 309 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 87 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 350 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 872 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 911 | 0.030 |
Why?
|
| Hypertension | 1 | 2017 | 524 | 0.030 |
Why?
|
| Ohio | 1 | 2011 | 23 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 86 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 105 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 96 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2011 | 134 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 243 | 0.020 |
Why?
|
| Disease Notification | 1 | 2007 | 7 | 0.020 |
Why?
|
| Health Resources | 1 | 2007 | 38 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 53 | 0.020 |
Why?
|
| Hospitals | 1 | 2007 | 80 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 275 | 0.020 |
Why?
|
| Endocarditis | 1 | 1982 | 1 | 0.010 |
Why?
|
| Yersinia enterocolitica | 1 | 1982 | 1 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1982 | 32 | 0.010 |
Why?
|
| Epidural Space | 1 | 2001 | 2 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2001 | 3 | 0.010 |
Why?
|
| Injections, Epidural | 1 | 2001 | 6 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 7 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2001 | 165 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1998 | 38 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1996 | 1 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1996 | 2 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 3 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 20 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 18 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1996 | 22 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 321 | 0.010 |
Why?
|
Concepts
(224)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->